Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy
for glioblastoma multiforme (GBM) and astrocytoma. A majority of patients do not respond to …

Gliomas are common and aggressive brain tumors that carry a poor prognosis. The current
multimodal therapeutic option for glioma includes surgery subsequently temozolomide …

Curcumin, a bioactive polyphenol, is known to have anticancer properties. In this study, the
effectiveness of curcumin pretreatment as a strategy for radio-sensitizing glioblastoma cell …

Central nervous system malignancies (CNSMs) are categorized among the most aggressive
and deadly types of cancer. The low median survival in patients with CNSMs is partly …

Although several antipsychotic drugs have been shown to possess anticancer activities,
haloperidol, a “first-generation” antipsychotic drug, has not been extensively evaluated for …

Glioma is the most prevailing main malignant neoplasm of the central nervous system with a
miserable prognosis. Temozolomide is the first-line chemotherapy drug for glioma, but its …

Hydroxy-3′, 4′, 6, 7-tetramethoxyflavone (TMF) is a plant-origin flavone known for its anti-
cancer properties. In the present study, the cytotoxic effect of TMF was evaluated in the …

Glioblastoma Multiforme (GBM) is the primary brain tumor and accounts for 200,000 deaths
each year worldwide. The standard therapy includes surgical resection followed by …

Temozolomide (TMZ) is used in the standard therapy regimen for patients with glioblastoma
(GBM). However, some GBM patients do not respond to TMZ therapy. The combining …

The aim of this study was to offer predicting factors for survival in adult patients with
glioblastoma multiforme. 153 consecutive patients with high-grade glioma (WHO grade IV) …